<DOC>
	<DOCNO>NCT00638365</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability single dose KB001 Cystic Fibrosis patient infect Pseudomonas aeruginosa ( Pa )</brief_summary>
	<brief_title>Dose Escalation Study KB001 Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa</brief_title>
	<detailed_description>CF patient often lung infection . Pseudomonas aeruginosa ( Pa ) significant bacteria CF , 80 % CF patient eventually become infect . These patient often treat antibiotic variable result . This study examine impact single-dose investigational drug , KB001 , Pa bacteria CF lung .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Written inform consent Confirmed diagnosis CF base follow criterion : Positive sweat chloride great 60mEq/liter , and/or genotype 2 identifiable mutation consistent CF , one clinical feature consistent CF phenotype Age &gt; /= 18 year age potential age 12 &gt; /= Screening Pa sputum culture FEV1 % predict &gt; /= 40 ( base Wang 's equation Males age 1217 female 1215 year , Hankinson 's equation patient ) Evidence acute respiratory infection pulmonary exacerbation within 4 week prior day 0 Use systemic corticosteroid antibiotic within 4 week prior day 0 , cyclic inhale antibiotic within 14 day prior day 0 . History positive B. cepacia complex , organ transplantation , hepatic disease venal dysfunction Current cigarette smoker , history drug addiction alcohol abuse Use investigational medication participation investigational study within 4 week prior day 0 Women pregnant breastfeeding patient and/or partner unwilling use effective form barrier contraception throughout study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cystic Fibrosis , Pseudomonas aeruginosa , Pulmonary CF</keyword>
</DOC>